UP Pharmaceutical Industry Policy, 2018 (read with #22)
This is a starter structure built directly from a policy guide's own FAQ content -
not independently verified. Confirm every incentive rate, cap, threshold and eligibility condition
against the notified policy PDF and the latest Government Order before advising an investor or
sanctioning a claim.
At a Glance
| Nodal Department / Agency | Infrastructure & Industrial Development Dept. |
|---|---|
| Primary Target | Legacy pharma units with existing eligibility |
| Policy Group | Pharma & health |
Frequently Asked Questions
Is this still live?
What did it cover?
Can a unit switch to the 2023 policy?
What should a district officer check?
Is this still live?
It is retained primarily for units that obtained eligibility under it. New pharma projects should apply under the 2023 policy.
What did it cover?
Formulation and API units, with capital subsidy, interest subsidy and stamp duty relief.
Can a unit switch to the 2023 policy?
Only with the sanctioning committee's approval and before an Eligibility Certificate is issued; not after.
What should a district officer check?
Whether the investor's LoC or registration date falls in the 2018 or 2023 window — this determines entitlement.